← Back to ALLO

Allogene Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 12/08/2026Mar 2026Filed 12/08/2026Sep 2025Filed 06/11/2025Jun 2025Filed 12/08/2026Mar 2025Filed 12/08/2026Sep 2024Filed 06/11/2025Jun 2024Filed 06/11/2025Mar 2024Filed 06/11/2025
$4.6$0$0$0$0$0$0
−$43−$43−$41−$51−$60−$66−$66−$65
−$0.13−$0.18−$0.19−$0.23−$0.28−$0.32−$0.35−$0.38
329240222219215209190169

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.